• Ling Zhang, Gloria Kai Yan Tang, Songqiao Liu, Jing Cai, Wai Ming Chan, Yi Yang, Ping Chang, Tiantian Wei, Xinyu Liu, Qiang Yao, Minmin Wang, and Mark R Marshall.
• Division of Nephrology, West China Hospital of Sichuan University, Chengdu, China, zhanglinglzy@163.com.
• Blood Purif. 2019 Jan 1; 47 Suppl 3: 1-6.

BackgroundoXiris is a blood purification product that has been launched recently in China. In addition to renal function support and fluid management capabilities, it can also adsorb cytokines and endotoxins. This may complement standard treatment for septic acute kidney injury (AKI) patients to control the amplitude of systemic inflammatory response responsible for acute tissue and organ damage. Objectives of our study are to elucidate characteristics of septic AKI patients who respond to treatment with oXiris and to describe the performance of oXiris through patient cases in the absence of large randomized trials on clinical use of oXiris for septic AKI patients in China.SummaryHere, we present 4 cases managed in intensive care units of major hospitals in China. Key practical aspects from an expert meeting discussing these cases have been included as guidance for the use of oXiris in septic AKI patients. Key Messages: Based on the experience gathered from 4 cases, oXiris should be used early in the treatment of septic AKI patients as an adjuvant therapy with good infection source control. It should not be used to delay or replace infection source control. These cases also demonstrated that patients with high risk of bleeding can use oXiris without additional anticoagulation for up to 36 h without implications on serum protein levels and platelet count. Short of definitive biomarkers to gauge the ideal blood purification initiation and discontinuation time for septic AKI patients, clinical judgment is key to determining optimal use of oXiris in septic AKI patients.© 2019 The Author(s). Published by S. Karger AG, Basel.

20 keywords...

hide…